# The Role of the Intestinal Mycobiome in Alcoholic Liver Disease

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $499,298

## Abstract

Project Summary
Alcohol associated health problems are a major medical burden in industrialized countries. Patients with
alcohol-associated liver disease show intestinal bacterial dysbiosis and increased intestinal permeability.
Although there is considerable progress in understanding the interaction between the host and intestinal
bacteria, the role of the intestinal fungal microbiome (also called mycobiome) in alcohol-associated liver
disease is not very well understood. Results from our laboratories indicate a proportional increase of
Candida albicans (C. albicans) and Malassezia restricta (M. restricta) in patients with alcohol use disorder.
Results from chronic ethanol administration in mice or chronic alcohol abuse in patients show that
C. albicans-specific T cell responses occur in the intestine. CD4+ T cells re-circulate to the liver, where they
re-activate by translocated C. albicans antigens, produce interleukin 17 (IL17) and contribute to progression
of ethanol-induced steatohepatitis. In addition, products from M. restricta translocate from the gut lumen to
the systemic circulation and liver. M. restricta induces liver inflammation via ligation with the Dectin-2
(Clec4n) receptor on Kupffer cells and augments ethanol-induced liver disease in mice. The testable central
hypothesis of this proposed collaborative and multidisciplinary research application implicates disturbances
in the gut fungal mycobiota as an important etiological factor in the modulation of adaptive and innate
immunity in the liver. Through the proposed study, we will characterize the host gut mycobiome and
immune response in a human cohort. We will mechanistically test our hypothesis in a mouse model of
ethanol-induced liver disease. Towards this goal, we will use pharmacological interventions,
supplementation of fungi and genetically modified mice. We predict that two pathogenic factors contribute to
dysfunction of the gut-liver axis in alcohol-associated liver disease: C. albicans overgrowth drives Th17 cell
expansion contributing to liver inflammation and damage (Aim 1). Binding of M. restricta to Dectin-2 induces
hepatic inflammation and exacerbates alcohol-associated liver disease (Aim 2). We believe these studies
will provide important insights into alcohol-mediated changes of the intestinal mycobiome that result in an
immune response contributing to alcohol-associated liver disease. Eventually this approach might lead to
new therapeutic targets for patients with alcohol-associated liver disease.

## Key facts

- **NIH application ID:** 10652248
- **Project number:** 5R01AA024726-07
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Bernd G. Schnabl
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $499,298
- **Award type:** 5
- **Project period:** 2017-06-01 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10652248

## Citation

> US National Institutes of Health, RePORTER application 10652248, The Role of the Intestinal Mycobiome in Alcoholic Liver Disease (5R01AA024726-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10652248. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*